Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer
暂无分享,去创建一个
S. Larson | P. Scardino | H. Scher | Jason S. Lewis | B. Beattie | H. Lilja | M. McDevitt | S. Strand | D. Veach | Philip A. Watson | D. Abou | D. Thorek | T. Gondo | O. V. Timmermand | S. Sharma | Sai Kiran Sharma | D. Ulmert | T. Hashimoto | T. Kalidindi
[1] E. Estey,et al. Phase I trial of alpha-particle immunotherapy with 225Ac-lintuzumab and low-dose cytarabine in patients age 60 or older with untreated acute myeloid leukemia. , 2017 .
[2] J. E. Mattson,et al. A Radium-223 microgenerator from cyclotron-produced trace Actinium-227. , 2017, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[3] S. Larson,et al. Internalization of secreted antigen–targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis , 2016, Science Translational Medicine.
[4] F. Saad,et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. , 2016, The Lancet. Oncology.
[5] S. Koochekpour,et al. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer , 2016, Oncotarget.
[6] F. Mottaghy,et al. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer , 2016, The Journal of Nuclear Medicine.
[7] T. Tran,et al. Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2 , 2016, EJNMMI Research.
[8] R. Baum,et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy , 2016, The Journal of Nuclear Medicine.
[9] M. Doucet,et al. Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis , 2015, Journal of the National Cancer Institute.
[10] D. Tindall,et al. Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. , 2015, Cancer research.
[11] H. Lilja,et al. Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6 , 2014, EJNMMI Research.
[12] C. Livi,et al. Analysis of Prostate-Specific Antigen Transcripts in Chimpanzees, Cynomolgus Monkeys, Baboons, and African Green Monkeys , 2014, PloS one.
[13] T. H. van der Kwast,et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.
[14] F. Feng,et al. A hormone-DNA repair circuit governs the response to genotoxic insult. , 2013, Cancer discovery.
[15] H. Hieronymus,et al. Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.
[16] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[17] S. Larson,et al. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. , 2012, Cancer discovery.
[18] Max E Valentinuzzi,et al. SAFETY AND EFFICACY , 2010 .
[19] D. Troyer,et al. Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases , 2008, The Prostate.
[20] D. Scheinberg,et al. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[22] D. Scheinberg,et al. Design and synthesis of 225Ac radioimmunopharmaceuticals. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[23] J. Humm,et al. Targeted α particle immunotherapy for myeloid leukemia , 2002 .
[24] D. Scheinberg,et al. Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.
[25] R L Vessella,et al. Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .
[26] H. Lilja,et al. Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. , 1999, European journal of biochemistry.
[27] D. Scheinberg,et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] E. Ward,et al. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. , 1997, Journal of immunology.
[29] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.